Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says
() -- Opus Genetics' (IRD) alignment with the US Food and Drug Administration on the design of the registrational phase 3 study of OPGx-LCA5, an investigational gene therapy for a rare inherited retinal disease, marks an important milestone, Wedbush Securities said Monday. The finalization of the study size at eight pa